EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis

Amar Miglani, Zachary M Soler, Timothy L Smith iD, Jess C Mace, Rodney J Schlosser

International Forum of Allergy & Rhinology · 2023-02 · 13 (2) · 116-128

DOI: 10.1002/alr.23059 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 04.09.2022. Verfasst von Amar Miglani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head & Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA. Hauptthemen laut MEDLINE: Nasal Polyps, Rhinitis, Sinusitis, Biological Products. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCD NIH HHS, National Institute on Deafness and Other Communication Disorders.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Comparative effectiveness research between endoscopic sinus surgery (ESS) and biologic therapy for severe chronic rhinosinusitis with nasal polyposis (CRSwNP) is a nascent field as new therapeutic modalities become clinically available.

Methods

A prospective, multicenter cohort of CRSwNP patients, undergoing ESS between 2011 and 2019, were compared to phase‐3 biologic trial data. Patients undergoing ESS received baseline nasal endoscopy quantified via Lund‐Kennedy (LK) grading. Patients meeting inclusion criteria, modified from Dupilumab‐LIBERTY‐NP‐24&52, omalizumab‐POLYP‐1&2, and Mepolizumab‐SYNAPSE clinical trials, were included in this study. Baseline characteristics and outcome measures were compared between these cohorts at 24 weeks and 52 weeks, when possible.

Results

A total of 111 CRSwNP patients met modified inclusion criteria. There were no statistically significant differences in baseline age, sex, asthma status, aspirin‐exacerbated respiratory disease status, smell identification, LK‐polyp score, and Lund‐Mackay computed tomography (CT) scores between ESS and biologic groups. At 24 weeks, ESS demonstrated significantly greater improvements in 22‐item Sino‐Nasal Outcome Test (SNOT‐22) compared to one (of two) dupilumab trials ( p < 0.05) and both omalizumab trials ( p < 0.001). ESS associated with significantly lower nasal polyp scores (NPS) compared to dupilumab ( p < 0.001) and omalizumab ( p < 0.001), despite comparable improvements in smell identification ( p > 0.05). At 52 weeks, ESS resulted in statistically similar improvement in SNOT‐22 scores compared to dupilumab ( p = 0.21), but NPS remained significantly lower in the ESS group compared to dupilumab ( p < 0.001) and mepolizumab ( p < 0.001).

Conclusion

At 24 weeks and 52 weeks, ESS offers comparable SNOT‐22 improvements compared to dupilumab. ESS and dupilumab offer comparable improvement in smell identification at 24 weeks. Compared to omalizumab, ESS offers superior SNOT‐22 improvements. ESS offers significantly greater reductions in polyp size compared to omalizumab, dupilumab, and mepolizumab therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasal PolypsRhinitisSinusitisBiological ProductsHumansProspective StudiesOmalizumabEndoscopyChronic DiseaseTreatment Outcome

Stichwörter der Autor:innen

chronic diseasechronic rhinosinusitisendoscopic sinus surgeryeosinophilic rhinitisnasal polyposisoutcome assessment (health care)quality of lifesinusitis

Substanzen

OmalizumabBiological Products

Autor:innen und Institutionen

  • Department of Otolaryngology-Head & Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Department of Otolaryngology-Head & Neck Surgery, Oregon Health & Science University, Portland, Oregon, USA.
  • Department of Surgery, Ralph H. Johnson VA Medical Center, Charleston, South Carolina, USA.

ORCID-Profile: Timothy L Smith

Förderung

  • NIDCD NIH HHS
  • National Institute on Deafness and Other Communication Disorders

Zitieren

APA

Miglani, A., Soler, Z. M., Smith, T. L., Mace, J. C., & Schlosser, R. J. (2023). A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis. International Forum of Allergy & Rhinology, 13(2), 116-128. https://doi.org/10.1002/alr.23059

Vancouver

Miglani A, Soler ZM, Smith TL, Mace JC, Schlosser RJ. A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis. International Forum of Allergy & Rhinology. 2023;13(2):116-128. doi:10.1002/alr.23059

BibTeX
@article{Miglani2023,
  author = {Miglani, Amar and Soler, Zachary M and Smith, Timothy L and Mace, Jess C and Schlosser, Rodney J},
  title = {A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis},
  journal = {International Forum of Allergy & Rhinology},
  year = {2023},
  volume = {13},
  number = {2},
  pages = {116--128},
  doi = {10.1002/alr.23059}
}
Kostenlos starten →